Diamyd Medical strengthens GABA portfolio with new license

Diamyd Medical has concluded a new exclusive licensing agreement with University of California, Los Angeles (UCLA) Technology Development Group on behalf of UC Regents. The license relates to new patent applications for the therapeutic use of GABA (gamma-aminobutyric acid) with positive allosteric modulators of the GABAA receptor to enhance beta cell regeneration, survival and immunomodulation.“This new GABA license together with our existing license, patent applications, and our proprietary GABA study drug Remygen®, provide a strong development platform to fully realize the therapeutic and